---
source_pdf: "https://drive.google.com/file/d/1Ke-KIhgH8MRMalt0iJVb4iWtZVKo_z8H/view"
drive_folder: "Portfolio/Prudentia"
type: portfolio
company: Prudentia
ingested: 2025-12-27
original_filename: "Copy of Prudentia Sciences Overview [Seed Investors] - non confidential .pptx"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/1Ke-KIhgH8MRMalt0iJVb4iWtZVKo_z8H/view)

## Slide 1

Confidential

PRUDENTIA SCIENCES

Sadiqa Mahmood

CEO and Founder
sm@prudentiasciences.com

Prepared for Seed Investors
Updated: August 1st 2024

‹#›

AI platform to unlock clinical and commercial success of a drug

Confidential - Do not distribute

---

## Slide 2

Confidential

Head of Engineering

PRANATHI VANGEEPURAM

Chief Technology Officer

JOHN REYNDERS, PhD

Head of Sales

ADHAM CHEBBANI

‹#›

Our Team

Confidential - Do not distribute

---

## Slide 3

Confidential

Our Board Members, Advisors and Investors

TRAVIS MAY (Advisor)
CEO, Shaper Capital
Co-Founder and CEO, Datavant ($7B M&A with Ciox)
Co-Founder and CEO, LiveRamp ($310M acquisition by Acxiom)

‹#›

JOE VON RICKENBAC (Advisor)
Senior Advisor at General Atlantic  
Co-Founder and CEO of PAREXEL ($8.5B acquisition by EQT and Goldman Sachs)
Co-Founder and CEO of Helio Vision (merged with Aldeyra, Inc. (NASDAQ: ALDX))

WASIM MALIK (Investor & Broad Member)
Managing Partner, Iaso Ventures
Chief Digital Strategist, Roivant ($7B IPO)
Director, Clinical Trial Network and Institute, Mass General Hospital

Confidential - Do not distribute

INVESTORS

---

## Slide 4

Confidential

Integrated Product Profile is the Foundation of Drug Asset Strategy

Discovery

Medical Affair

Regulatory Affairs

Commercial

‹#›

Ph I

Ph II

Ph III

Ph IV

IPP

Label

Clinical Development & Operations

Integrated Product Profile (IPP) defines ideal drug profiles outlining the path to an approved drug label. It is used by various stakeholders throughout product lifecycle.

Current challenge is that building IPP is a manual and complex process to develop scientific, commercial and BD&L strategy.

Stakeholders

Confidential - Do not distribute

---

## Slide 5

Confidential

Prudentia Sciences - AI platform to unlock clinical and commercial success of a drug

Assess Competitor Landscape

Test Scenarios for Clinical, Commercial and Regulatory Success

Generate IPP
 using AI

Design a data driven real-time Integrated Product Profile (IPP)

‹#›

Confidential - Do not distribute

---

## Slide 6

Confidential

Immediate Market Opportunity

‹#›

$50B
Annual Global Clinical Trial Market 

5.8%
CAGR 2023 to 2030

$18B
Spent on clinical trial design segment (TAM)


$5.5B
IPP for every trial start (SAM)*

*conservative pricing at $1M avg spend per trial per asset

Growing number of trial starts per year 
and increasing complexity of trials 
requires real-time Integrated Product Profile

Source: Citeline Trialtrove, Jan 2024; IQVIA Institute, Jan 2023

Confidential - Do not distribute

---

## Slide 7

Confidential

Competitive Landscape

‹#›

Quant Health: clinical endpoint simulation
Yesop: medical writing and clinical documentation
Zephyr AI: focused on clinical outcomes
BenchSci: drug discovery platform

The following AI companies are not focused on IPP generation::

Confidential - Do not distribute

---

## Slide 8

Confidential

Our Progress

Data Partnerships
Access to proprietary information

Clinically Trained AI
AI is clinical, regulatory and commercial informed

Confidential - Do not distribute

---

## Slide 9

Confidential

Vision – End to End Portfolio Strategy and Management

‹#›

Discovery

Commercialization

Engagement Throughout Product Life Cycle

Asset to Portfolio Strategy Design & Management

$30B- $50B TAM

Confidential - Do not distribute

Clinical Development Plan